Dr. Anjali Anil Bharne, MD

Dr. Bharne practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Bharne's NPI, 1053519280, was assigned on July 10, 2007. Dr. Bharne graduated from Keck School of Medicine of USC in 2004. Dr. Bharne holds California license A94639.

Dr. Bharne's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Bharne's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Bharne is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Bharne to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bharne practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bharne's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bharne is board certified in hematology by the American Board of Internal Medicine. Dr. Bharne is licensed in California.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, lung cancer, lymphoma, neutropenia and prostate cancer among the conditions Dr. Bharne treats.

CMS data shows 22,079 Medicare services from Dr. Bharne across 26 procedure codes in 2024, for 373 Medicare patients. Medicare paid $172,939 for them. Every service was in an office.

CMS counts 373 Medicare patients who saw Dr. Bharne in 2024. The largest group is 75 to 84, with 157 patients. 66% of them have high blood pressure, and 66% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bharne's median patient age at 63, with 64% women.

In 2024, Dr. Bharne wrote 427 Medicare Part D claims for 74 patients. 71% of them were for generic drugs. CMS names the drug for 231 of them, across 14 drugs with 11 or more claims each, at $616,216 in total drug cost. In 2023, CMS named 258 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Bharne for performance year 2024, reported as part of a group. Dr. Bharne accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bharne as offering telehealth.

Dmand AI links 6 papers to Dr. Bharne, published from 2010 to 2018. 2011 was the busiest year, with 2. The most frequent topics are Lung Neoplasms, Positron-Emission Tomography and Radiosurgery. Dr. Bharne's most frequent co-authors are Mark M. Fuster, MD, Joshua D. Lawson, MD and Arno James Mundt, MD.

CMS Open Payments shows 14 general payments to Dr. Bharne from 9 drug and device companies from 2017 to 2023. Consulting fees make up the largest share, 67% of the total. AstraZeneca Pharmaceuticals LP paid the most, $1,642.

Dmand AI lists 1 award for Dr. Bharne, most recently CMS Stage 1 EHR in 2013.

Dr. Bharne graduated from Keck School of Medicine of USC in 2004.

Dr. Bharne is in network with 12 carriers, including Aetna, Elevance and United Healthcare. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.